Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Celgene’s Abraxane Scores A Win Against Tough Pancreatic Cancer

Executive Summary

Abraxane more than doubled two-year survival and conferred a near-two-month overall survival advantage against pancreatic cancer compared with standard of care gemcitabine alone in the Phase III MPACT trial, presented Jan. 25 at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium in San Francisco. Celgene plans global regulatory filings by mid-2013.

You may also be interested in...



Celgene’s Budding Blockbuster Abraxane Scoops Pancreatic Cancer Indication

Abraxane sales have been growing fast as Celgene has added new indications. Pancreatic cancer had been an off-label use prior to the new approval.

Immune/EpiCept Merge To Form Multi-Project Antibody Drug Company

Israeli antibody drug developer Immune Pharmaceuticals will have several projects in the pipeline, including some potential out-licensing candidates, after it makes the leap to a U.S. public company through a reverse-merger with troubled EpiCept, CEO Daniel Teper said during an interview at BIO CEO.

Celgene Lays Out Catalysts For Strong 2013, Highlights Apremilast

Celgene reported strong sales for key products, led by Revlimid, during its year-end 2012 call. The biopharma affirmed 2013 guidance, detailing the key regulatory and commercial drivers that will power the global expansion of its hematology, oncology, and immunology franchises. In particular, it highlighted the commercial potential for apremilast.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS055064

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel